|
1 Indications And Usage Unituxin (Dinutuximab) Is Indicated, In Combination With Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf), Interleukin-2 (Il-2) And 13-Cis-Retinoic Acid (Ra), For The Treatment Of Pediatric Patients With High-Risk Neuroblastoma Who Achieve At Least A Partial Response To Prior First-Line Multiagent, Multimodality Therapy [See Clinical Studies (14) ]. Unituxin Is A Gd2-Binding Monoclonal Antibody Indicated, In Combination With Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf), Interleukin-2 (Il-2), And 13-Cis-Retinoic Acid (Ra), For The Treatment Of Pediatric Patients With High-Risk Neuroblastoma Who Achieve At Least A Partial Response To Prior First-Line Multiagent, Multimodality Therapy. ( 1 )
|